Literature DB >> 18840395

Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation.

Lukasz A Malek1, Lidia Chojnowska, Mariusz Klopotowski, Renata Maczynska, Marcin Demkow, Adam Witkowski, Beata Kusmierczyk, Ewa Piotrowicz, Marek Konka, Maciej Dabrowski, Witold Ruzyllo.   

Abstract

BACKGROUND: In hypertrophic obstructive cardiomyopathy, percutaneous transluminal septal myocardial ablation (PTSMA) improves functional capacity in the short term. However, long term functional capacity is unknown. AIM: To assess the long term exercise capacity of patients with hypertrophic obstructive cardiomyopathy undergoing PTSMA.
METHODS: Twenty three patients (56.5% male, mean age 44.5+/-13.6 years) who underwent PTSMA were included. All patients had also undergone a symptom limited cardiopulmonary exercise treadmill test before the procedure, then after 3 months (early follow-up) and after a mean 7.2+/-1.0 years (long term follow-up).
RESULTS: Before PTSMA, mean maximal pressure gradient in the left outflow tract (LVOTGmax) was 82+/-29 mmHg, 17 patients had NYHA functional class> or = III and peak oxygen uptake (pVO2) was 18+/-4 ml/kg/min. PTSMA led to a reduction in mean LVOTGmax (to 29+/-19 mmHg, p<.0001), improvement of heart failure symptoms (NYHA> or =III in 1 patient, p<.0001) and an increase of pVO2 (to 22+/-6 ml/kg/min, p=.0002) at short term. LVOTGmax, functional class and pVO2 did not change significantly during long term follow-up compared to early follow-up. However, there was a continuous improvement in percentage predicted pVO2 over time.
CONCLUSIONS: In patients with hypertrophic obstructive cardiomyopathy and symptoms of heart failure, PTSMA leads to stable long term improvement of objectively measured exercise capacity.

Entities:  

Mesh:

Year:  2008        PMID: 18840395     DOI: 10.1016/j.ejheart.2008.09.005

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  4 in total

1.  The risk of non-sustained ventricular tachycardia after percutaneous alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Mariusz Klopotowski; Lidia Chojnowska; Lukasz A Malek; Renata Maczynska; Krzysztof Kukula; Marcin Demkow; Adam Witkowski; Maciej Dabrowski; Maciej Karcz; Rafal Baranowski; Beata Kusmierczyk-Droszcz; Mariusz Kruk; Jacek Jamiolkowski; Mariusz Kusmierczyk; Lukasz Szumowski; Witold Ruzyllo
Journal:  Clin Res Cardiol       Date:  2010-02-11       Impact factor: 5.460

2.  Characteristics of myocardial postsystolic shortening in patients with symptomatic hypertrophic obstructive cardiomyopathy before and half a year after alcohol septal ablation assessed by speckle tracking echocardiography.

Authors:  Jiansong Yuan; Shi Chen; Shubin Qiao; Fujian Duan; Jiafen Zhang; Hao Wang
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

3.  Comparison of sublingual isosorbide dinitrate and Valsalva maneuver for detection of obstruction in hypertrophic cardiomyopathy.

Authors:  David Zemanek; Pavol Tomasov; Miloš Bělehrad; Katarína Hladká; Jana Košťálová; Tomáš Kára; Josef Veselka
Journal:  Arch Med Sci       Date:  2015-01-14       Impact factor: 3.318

4.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy - 8 years follow up.

Authors:  I Sathyamurthy; Rajeshwari Nayak; Abraham Oomman; K Subramanyan; Mathew Samuel Kalarical; Robert Mao; P Ramachandran
Journal:  Indian Heart J       Date:  2013-12-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.